IP Library Granted Patent US 9,918,656
Granted Patent B2
US 9,918,656 · App. 13/806,348 · Granted Mar 20, 2018

Implantable magnetic relaxation sensors and methods of measuring a sensor's cumulative exposure to a biomarker

Inventors: Michael J. Cima (Winchester, MA); Paul Huang (Boston, MA); Yibo Ling (Brooklyn, NY); Terrence Pong (San Francisco, CA); Christophoros C. Vassiliou (Cambridge, MA)
Assignees: Massachusetts Institute of Technology; The General Hospital Corporation
A61B5/055A61B5/0031A61B5/14546G01R33/5601A61B2562/0285G01R33/302G01R33/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,918,656
App. No.
13/806,348
Granted
Mar 20, 2018
Kind
B2
Abstract

An implantable magnetic relaxation sensor is provided that comprises superparamagnetic nanoparticies functionalized with one or more agents that bond with a biomarker of interest. The sensor is configured for minimally-invasive implantation into a human or animal, and is configured to indicate the implanted sensor's cumulative exposure to the biomarker of interest by analysis using magnetic resonance relaxometry.

Claims (21)

1. An implantable magnetic relaxation sensor comprising:

superparamagnetic nanoparticles functionalized with one or more agents that irreversibly bond with a biomarker of interest;

wherein the sensor is configured for minimally-invasive implantation into a human or animal; and

wherein the sensor is configured to operate as a dosimeter to indicate the implanted sensor's cumulative exposure to the biomarker of interest with a single reading of the sensor by analysis using magnetic resonance relaxometry.

2. The sensor of claim 1 , wherein the one or more agents comprise an antibody.

3. The sensor of claim 2 , wherein the one or more agents comprise antibodies for myoglobin, cTnI, CK-MB, or a combination thereof.

4. The sensor of claim 3 , wherein the biomarker of interest is myoglobin, cTnI, CK-MB, or a combination thereof; and wherein the sensor is configured to indicate the sensor's cumulative exposure to myoglobin, cTnI, CK-MB, or a combination thereof after the sensor has been implanted and the sensor is analyzed using magnetic resonance relaxometry.

5. The sensor of claim 4 , wherein the sensor is sensitive to cTnI in a range of 10-100 ng/mL.

6. The sensor of claim 4 , wherein the sensor is sensitive to myoglobin in a range of 100 ng/mL to 1 μg/mL.

7. The sensor of claim 4 , wherein the sensor is sensitive to CK-MB in a range of 100 ng/mL to 1 μg/mL.

8. The sensor of claim 1 , wherein the nanoparticles comprise iron oxide.

9. The sensor of claim 1 , further comprising a sensor body having at least one reservoir, wherein the nanoparticles are contained within the at least one reservoir.

10. The sensor of claim 9 , wherein the nanoparticles are retained within the at least one reservoir by one or more size-exclusion membranes.

11. An implantable magnetic relaxation sensor comprising:

superparamagnetic nanoparticles functionalized with one or more antibodies that irreversibly bond with myoglobin, cTnI, CK-MB, or a combination thereof;

wherein the sensor is configured to operate as a dosimeter to indicate the sensor's cumulative exposure to myoglobin, cTnI, CK-MB, or a combination thereof with a single reading of the sensor by analysis using magnetic resonance relaxometry after the sensor has been implanted, and wherein the sensor comprises a sensor body having at least one reservoir, wherein the nanoparticles are contained within the at least one reservoir.

12. The sensor of claim 11 , wherein the nanoparticles comprise iron oxide.

13. The sensor of claim 11 , wherein the nanoparticles are retained within the at least one reservoir by one or more size-exclusion membranes.

14. The sensor of claim 11 , wherein the sensor is sensitive to cTnI in a range of 10-100 ng/mL.

15. The sensor of claim 11 , wherein the sensor is sensitive to myoglobin in a range of 100 ng/mL to 1 μg/mL.

16. The sensor of claim 11 , wherein the sensor is sensitive to CK-MB in a range of 100 ng/mL to 1 μg/mL.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2013
From: CIMA, MICHAEL J.; LING, YIBO; PONG, TERRENCE; VASSILIOU, CHRISTOPHOROS C.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 029840/0366 →
CONFIRMATORY LICENSE Recorded Jan 23, 2013
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029675/0852 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2013
From: HUANG, PAUL
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 029640/0513 →
Continuity (2)
Provisional Application 61358449 · Jun 25, 2010
Related Publication 20130150707A1 · Jun 13, 2013